Changshu Singmed Advanced Drug Delivery Device R&D and Manufacturing Base Commences Production, Large-Scale Capacity Boosts Domestic Substitution of Inhalation Formulations
Asia's Largest DPI & SMI Drug Delivery Device R&D and Manufacturing Base Commences Production, Milestone Breakthrough in Domestic High-End Inhalation Drug Delivery Device Production
On August 6, Singmed Medical Device Technology Co., Ltd. (hereinafter referred to as "Singmed") held a grand ceremony to mark the commencement of production at its Changshu Drug Delivery Device R&D and Manufacturing Base in the Changshu Economic And Technological Development Zone.
It is reported that this base is currently the largest aerosol drug delivery device (DPI & SMI) and high-end pharmaceutical packaging material manufacturing base in Asia. It is primarily used for the research, development, and manufacturing of drug delivery devices and pharmaceutical packaging materials. The commencement of production will further meet the growing capacity demands of the inhalation drug delivery market, promoting the robust development of the domestic inhalation drug delivery sector.
Dr. Qing Zhu, Founding Partner of Hongyuan Capital, stated, "In recent years, our deepening understanding of respiratory diseases has led to the flourishing of the inhalation drug industry. The market size for inhalation drug delivery in China has been expanding year by year, yet there is a significant gap in drug delivery devices. Singmed is the first domestic company to break through the technological barriers of drug delivery devices and successfully pass the BE consistency evaluation. Hongyuan Capital is pleased to see that Singmed's Changshu Economic And Technological Development Zone drug delivery device R&D and production base has been established and put into operation at an extremely rapid pace. This will contribute high-quality capacity to the thriving inhalation drug industry in China, benefiting numerous patients with chronic respiratory diseases."
Dr. Qing Zhu
Founding Partner of Creacion Ventures
Albert Zhao, Founder of Singmed, stated, "In less than a year, we have completed the construction of our factory, relocation of equipment, and system validation, establishing China's largest R&D and manufacturing base for DPI and SMI pulmonary drug delivery devices. In the complex drug delivery systems field for high-end pulmonary and nasal spray drug delivery, which has long been monopolized by foreign giants, we have achieved technological breakthroughs and mass production on a commercial scale. We now have the capability to commercially supply a full range of DPI and SMI products. Additionally, we have built industry-leading R&D hardware and teams, promoting high-end generics and innovative development of drug-device combination products, driving rapid development in domestic substitution."
"The launch of the production line at the Changshu base is a significant milestone for Singmed and marks a new starting point for future business development," said Albert Zhao, Founder of Singmed. "For many years, we have been deeply involved in the inhalation drug sector, leveraging our years of technical accumulation to continuously innovate our products and meet the growing demands of our customers. It took us only 11 months to complete the construction of the factory, a feat that would not have been possible without the strong support from the Changshu Economic And Technological Development Zone. This also reflects the powerful impetus the Changshu Economic And Technological Development Zone provides for enterprise development."
Albert Zhao
Founder of Singmed
The Singmed Changshu drug delivery device R&D and production base project is planned to cover an area of 40 mu, with a total investment of approximately 500 million yuan. The completion of this base not only enhances production capacity to meet the growing market demand for integrated services in customized R&D, design, and production, but also represents a significant milestone in the domestic inhalation drug delivery industry.
The first phase of the Singmed Changshu base has completed the construction of a 20,000-square-meter GMP standard plant, with 8,000 square meters of ISO-8 and ISO-7 grade clean rooms. The facility has introduced world-class injection molding machines from Sumitomo and Fanuc and has simultaneously developed commercial silicon-based atomization chip production and high-precision testing equipment in-house. It is understood that the project is planned to have an annual production capacity of 50 million drug delivery devices and 2.5 billion pharmaceutical packaging materials. The initial phase's production capacity is set at 30 million drug delivery devices and 1.5 billion pharmaceutical packaging materials per year. Achieving this production capacity will significantly enhance Singmed's competitiveness and market share in the inhalation drug sector.
